NewAmsterdam Pharma Co NV (FRA:KH6) Total Liabilities : €102.30 Mil (As of Dec. 2024)

View and export this data going back to 2022. Start your Free Trial

What is NewAmsterdam Pharma Co NV Total Liabilities?

NewAmsterdam Pharma Co NV's Total Liabilities for the quarter that ended in Dec. 2024 was €102.30 Mil.

NewAmsterdam Pharma Co NV's quarterly Total Liabilities declined from Jun. 2024 (€55.04 Mil) to Sep. 2024 (€54.36 Mil) but then increased from Sep. 2024 (€54.36 Mil) to Dec. 2024 (€102.30 Mil).

NewAmsterdam Pharma Co NV's annual Total Liabilities increased from Dec. 2022 (€45.72 Mil) to Dec. 2023 (€53.83 Mil) and increased from Dec. 2023 (€53.83 Mil) to Dec. 2024 (€102.30 Mil).

NewAmsterdam Pharma Co NV Total Liabilities Historical Data

The historical data trend for NewAmsterdam Pharma Co NV's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NewAmsterdam Pharma Co NV Total Liabilities Chart

NewAmsterdam Pharma Co NV Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

Total Liabilities

12.95

10.01

45.72

53.83

102.30

NewAmsterdam Pharma Co NV Quarterly Data
	Dec20	Dec21	Jun22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Total Liabilities	Get a 7-Day Free Trial							53.83	70.53	55.04	54.36	102.30

NewAmsterdam Pharma Co NV Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

NewAmsterdam Pharma Co NV's Total Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	102.107	+	(0.193	+	-2.1649348980191E-15
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	102.30

Total Liabilities	=	Total Assets (A: Dec. 2024 )	-	Total Equity (A: Dec. 2024 )
	=	825.712	-	723.413
	=	102.30

NewAmsterdam Pharma Co NV's Total Liabilities for the quarter that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	102.107	+	(0.193	+	-2.1649348980191E-15
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	102.30

Total Liabilities	=	Total Assets (Q: Dec. 2024 )	-	Total Equity (Q: Dec. 2024 )
	=	825.712	-	723.413
	=	102.30

NewAmsterdam Pharma Co NV Total Liabilities Related Terms

Thank you for viewing the detailed overview of NewAmsterdam Pharma Co NV's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

NewAmsterdam Pharma Co NV Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NewAmsterdam Pharma Co NV (FRA:KH6) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

NAMS:USA

Address

Gooimeer 2-35, Naarden, NH, NLD, 1411 DC

Website

https://www.newamsterdampharma.com

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.

NewAmsterdam Pharma Co NV Headlines

No Headlines